ONO-6950 Phase 2a study

ONO-6950 Phase 2a study A multicenter, double-blind, randomized parallel-group study in patients with asthma.

Status

Unknown

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222716

Enrollment

100

Registered

2015-01-14

Start date

2015-01-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Interventions

investigational material(s) Generic name etc : ONO-6950 INN of investigational material : gemilukast Therapeutic category code : 449 Other antiallergic agents Dosage and Administration for Investigati

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. patients with ashtma

Exclusion criteria

Exclusion criteria: 1. Has a respiratory disorder other than asthma such as COPD and/or active tuberculosis 2. History of serious drug allergy 3. If female, are pregnant or breastfeeding

Design outcomes

Primary

Measure	Time frame
asthma symptom, respiratory function	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026